Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.
about
Subcutaneous versus intravenous erythropoietin for long-term dialysis patientsSubcutaneous versus intravenous erythropoietin for long-term dialysis patientsAnaemia management with subcutaneous epoetin delta in patients with chronic kidney disease (predialysis, haemodialysis, peritoneal dialysis): results of an open-label, 1-year study.The role of anemia management in improving outcomes for African-Americans with chronic kidney diseaseCosts Associated With Intravenous Darbepoetin Versus Epoetin Therapy in Hemodialysis Patients: A Randomized Controlled Trial.Biochemistry, physiology, and complications of blood doping: facts and speculation.Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome.Emerging technologies in the delivery of erythropoietin for therapeutics.Hematide™ for the treatment of chronic kidney disease-related anemia.Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.Clinical development of biosimilars: an evolving landscape.Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.Individualizing anaemia therapyDarbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP).
P2860
Q24187032-276F1624-1087-4C12-80FA-0E1CF5384BB4Q24200417-496CF2C2-751B-4CD1-9416-C4835B4303B9Q33412594-614CF317-878C-4D65-B642-CF72362090E7Q33646679-05A1D5CA-11C9-4617-AE3D-AD6400A23E96Q33887606-576B521D-7336-4582-BB29-FA1C38F1BD3DQ36504354-A7F144CE-2630-4555-B912-9B71BA760D17Q37598414-AAD52FC2-D0E7-4652-B41C-1F48FC282F80Q37646523-86983BFA-F5DD-4E05-B6B8-2253F23EFE9DQ37810076-E225FC9F-BCC9-43BC-B541-F7098617D8D3Q38075798-E64E2CA4-98D8-4DA2-A733-2F9346C8CA2EQ38083094-8307C587-9527-4C5D-92FE-2A4AD1172C13Q38126361-B1F27FCC-91DE-4627-B1BF-351F6684BA8EQ40329273-318816F5-434D-421B-B045-6940634B17DEQ41892226-9B055F8F-83EC-45A1-88D8-E0D7ACA11B02Q50627188-5A785072-7A7D-49F9-A98B-6D186BC6BB2F
P2860
Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Differentiating factors betwee ...... mia of chronic kidney disease.
@ast
Differentiating factors betwee ...... mia of chronic kidney disease.
@en
type
label
Differentiating factors betwee ...... mia of chronic kidney disease.
@ast
Differentiating factors betwee ...... mia of chronic kidney disease.
@en
prefLabel
Differentiating factors betwee ...... mia of chronic kidney disease.
@ast
Differentiating factors betwee ...... mia of chronic kidney disease.
@en
P1433
P1476
Differentiating factors betwee ...... mia of chronic kidney disease.
@en
P2093
Robert Deicher
Walter H Hörl
P304
P356
10.2165/00003495-200464050-00004
P577
2004-01-01T00:00:00Z
P6179
1003952942